Other studies have shown that GSK-J4 treatment inhibited proliferation of castration-resistant prostate cancer cells by inhibiting AR–driven transcription and can also inhibit proliferation in glioma cells in a dose-dependent manner in vitro (Morozov et al., 2017; Sui et al., 2017). Here, AR is linked to prostate carcinoma.